2-Methyl-1-[1-(2-methylpropanoyl)cyclobutyl]propan-1-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Methyl-1-[1-(2-methylpropanoyl)cyclobutyl]propan-1-one
• 英文别名: 2-methyl-1-[1-(2-methylpropanoyl)cyclobutyl]propan-1-one
• 化学式: C₁₂H₂₀O₂
• 分子量: 196.29
• InChiKey: GGHPIZVTCZZPTO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• IAP ANTAGONISTS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150322111A1

  公开（公告）日：2015-11-12

  There are disclosed compounds of formula (I) that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

  公开了化合物(I)的配方，该化合物调节凋亡抑制剂(IAPs)的活性，包含该化合物的药物组合物以及利用本发明的化合物治疗增生性疾病和失调凋亡疾病，如癌症的方法。
• [EN] MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT INHIBITEURS DE MCL-1 ET PROCÉDÉS D'UTILISATION
  申请人：NOVARTIS AG

  公开号：WO2022115451A1

  公开（公告）日：2022-06-02

  Anti-CD48 antibody-drug conjugates are disclosed. The anti-CD48 antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety and an anti-CD48 antibody or antigen-binding fragment thereof that binds an antigen target, e.g., an antigen expressed on a tumor or other cancer cell. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising an Mcl-1 inhibitor drug moiety and methods of making same are also disclosed.

  本文披露了抗CD48抗体药物结合物。该抗CD48抗体药物结合物包括Mcl-1抑制剂药物部分和抗CD48抗体或其抗原结合片段，其结合抗原靶点，例如在肿瘤或其他癌细胞上表达的抗原。本文进一步涉及使用所提供的抗体药物结合物治疗癌症的方法和组合物。还披露了包含Mcl-1抑制剂药物部分的连接体-药物结合物和制备方法。
• [EN] BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT INHIBITEURS DE BCL-XL ET LEURS PROCÉDÉS D'UTILISATION
  申请人：NOVARTIS AG

  公开号：WO2022115477A1

  公开（公告）日：2022-06-02

  Antibody-drug conjugates that bind to human oncology targets are disclosed. The antibody- drug conjugates comprise a Bcl-xL inhibitor drug moiety. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody- drug conjugates provided herein. Linker-drug conjugates comprising Bcl-xL inhibitor drug moiety and methods of making same are also disclosed.

  本文揭示了结合人类肿瘤靶点的抗体药物偶联物。这些抗体药物偶联物包括Bcl-xL抑制剂药物部分。本文还涉及使用本文提供的抗体药物偶联物治疗癌症的方法和组合物。本文还揭示了包含Bcl-xL抑制剂药物部分的连接剂-药物偶联物及其制备方法。
• US9783573B2
  申请人：——

  公开号：US9783573B2

  公开（公告）日：2017-10-10
• [EN] IAP ANTAGONISTS<br/>[FR] ANTAGONISTES D'IAP
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2014047024A1

  公开（公告）日：2014-03-27

  There are disclosed compounds of formula (I) that modulate the activity of inhibitors of apoptosis (lAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention. (Formula (I))